Goldman Sachs Group Inc Pep Gen Inc. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Pep Gen Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 58,802 shares of PEPG stock, worth $213,451. This represents 0.0% of its overall portfolio holdings.

Number of Shares

58,802

Holding current value

$213,451

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$7.75 - $18.55 $455,715 - $1.09 Million	58,802 New	58,802 $502,000
Q1 2024 May 15, 2024	SELL	$6.63 - $17.3 $6,252 - $16,313	-943 Reduced 6.66%	13,213 $194,000
Q4 2023 Feb 13, 2024	BUY	$3.86 - $7.96 $54,642 - $112,681	14,156 New	14,156 $96,000
Q2 2023 May 14, 2024	SELL	$8.94 - $16.39 $162,877 - $298,609	-18,219 Reduced 56.86%	13,825 $123,000
Q2 2023 Aug 14, 2023	SELL	$8.94 - $16.39 $162,877 - $298,609	-18,219 Reduced 56.86%	13,825 $123,000
Q1 2023 May 14, 2024	BUY	$11.44 - $17.7 $240,445 - $372,018	21,018 Added 190.62%	32,044 $391,000
Q1 2023 May 11, 2023	BUY	$11.44 - $17.7 $240,445 - $372,018	21,018 Added 190.62%	32,044 $391,000
Q4 2022 May 14, 2024	SELL	$9.31 - $16.57 $29,140 - $51,864	-3,130 Reduced 22.11%	11,026 $147,000
Q4 2022 Feb 13, 2023	BUY	$9.31 - $16.57 $102,652 - $182,700	11,026 New	11,026 $147,000

Others Institutions Holding PEPG

# of Institutions

Shares Held

25.2M

Call Options Held

Put Options Held

Ra Capital Management, L.P. Boston, MA

10.7M
Shares

$38.8 Million
1.27% of portfolio
Janus Henderson Group PLC London, X0

2.34M
Shares

$8.48 Million
0.01% of portfolio
Suvretta Capital Management, LLC New York, NY

1.66M
Shares

$6.03 Million
0.56% of portfolio
Viking Global Investors LP

1.48M
Shares

$5.38 Million
0.05% of portfolio
Perceptive Advisors LLC New York, NY

1.41M
Shares

$5.12 Million
0.32% of portfolio

View Full List

About PepGen Inc.

Ticker PEPG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,631,900
Market Cap $85.8M
Description
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is a...

More about PEPG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account